New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Prelude Therapeutics Incorporated (PRLD) vs Q32 Bio Inc. (QTTB)

Prelude Therapeutics Incorporated and Q32 Bio Inc. are both Biotechnology companies. Prelude Therapeutics Incorporated and Q32 Bio Inc. are of similar size ($260.5M and $253.8M). Prelude Therapeutics Incorporated has negative trailing earnings, so its P/E is not meaningful; Q32 Bio Inc. trades at 2.5×. Q32 Bio Inc. has the higher net margin (808.0% vs −247.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Q32 Bio Inc. leads on 12 and Prelude Therapeutics Incorporated on 0.

Valuation

Metric PRLD QTTB Biotechnology median
P/E n/m 2.49 8.49
P/S 15.44 n/m 8.56
P/B 2.68 0.99 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m 0.15 0.69
EV/Sales 8.95 0.78 8.00
Earnings yield (18.32%) 40.19% (35.81%)
Free cash flow yield (8.40%) (7.04%) (25.41%)

Profitability

Metric PRLD QTTB Biotechnology median
Gross margin 100.00% 100.00% 70.18%
Operating margin (283.92%) 725.53% 0.00%
Net margin (247.12%) 808.04% 0.00%
Free cash flow margin (129.68%) 280.89% 0.00%
Return on equity (58.36%) 23.96% (51.58%)
Return on assets (39.45%) 18.17% (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PRLD QTTB Biotechnology median
Revenue growth (TTM) — (307.33%) 7.20%
EPS growth (last fiscal year) 23.21% 136.78% 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric PRLD QTTB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.20 56.34 4.79
Net debt to EBITDA 1.00 (2.21) 1.01

Dividend

Metric PRLD QTTB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PRLD QTTB Biotechnology median
Market cap 260.48m 253.75m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack